Myo-inositol Cognition Randomized Trial: What the Evidence Says

Quick Answer

Myo-inositol Cognition Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 observational study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• To rigorously evaluate this impact, the 3-year randomized controlled MIND trial was conducted in cognitively unimpaired older adults with AD risk factors. [Voigt Robin M. (2026); evidence level 2]
• This study hypothesized that the MIND diet would induce unique, beneficial adaptations in the intestinal microbiome.,Additionally, by analyzing shotgun metagenomic data across the 3-year trial period, this study aimed to disentangle the impact of physiological change (i.e., weight loss, improved metabolic health) and dietary pattern on the intestinal microbiome. [Voigt Robin M. (2026); evidence level 2]
• Diet, a major lifestyle domain, is highly modifiable and has been identified as an important factor associated with cognitive decline. [Remie Lianne B. (2026); evidence level 3]
• Moreover, within healthy older- and middle-aged adults, a higher adherence to the MIND diet was associated with better cognitive performance, specifically within the global cognition and episodic memory domains. [Remie Lianne B. (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For myo-inositol cognition randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Voigt Robin M. (2026). Weight loss and metabolic improvements dominate the microbiome response in the MIND diet intervention: a randomized controlled trial. DOI: 10.1002/trc2.70239. PMCID: PMC13060763. PMID: 41958469. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open .... https://pmc.ncbi.nlm.nih.gov/articles/PMC13060763/
• Remie Lianne B. (2026). MIND-NL diet adherence moderates the relation of low-grade systemic inflammation with neuroinflammatory metabolites and cognitive functioning: an exploratory cross-sectional study in older adults. DOI: 10.1186/s12974-026-03773-8. PMCID: PMC13220514. PMID: 41957664. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13220514/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.